It is an exciting time to be a part of Team Aimedis. Pfizer Deutschland GmbH wants to partner up with Aimedis for a pharmacovigilance project for one of its speciality antibacterials. Aimedis is going to contribute to the project by collection and analysis of data of patients who undergo intensive care and follow them up even after discharge.
The pharmaceutical industry crossed a trillion dollars in 2014. Pfizer Inc is one of the largest pharmaceutical companies in the world, with a Market capitalisation of about USD 212.69 Billion. You may know them for their blockbuster drugs – Lipitor for lowering cholesterol, Advil for pain, and Viagra for erectile dysfunction.
In addition, they have an impressive lineup of biologicals – the state-of-the-art medicines that are helping people with cancer and other difficult-to-treat illnesses.
Pfizer, like any other pharmaceutical companies, develops, manufactures, and markets medicines, commonly referred to as pharmaceutical drugs. To ensure that these drugs are safe for human consumption, they are tested for safety and efficacy through a series of clinical trials. Only when the Medical regulatory authorities, like the EMEA or the US FDA thinks that these are sufficiently safe and effective, are they made available to the patients. These trials have from a few hundred to a few thousand patients and can go on for years.
Aimedis teams up with Pfizer Deutschland GmbH
The clinical trials today are quite rigorous. However, in the end, they are conducted only on a few thousand patients. So, the pharmaceutical companies do something called as a post-marketing surveillance, or pharmacovigilance.
Pharmacovigilance essentially entails looking out for any new adverse reactions to the medicines after they are available to the public. If you read any pack insert of a medicine you might be taking, you can see a number to call in case you experience any side effects. This is a part of Pharmacovigilance.
Aimedis is going to use the power of AI to better patient treatment, and here is how.
Pfizer has developed highly effective antibacterials that are used in critical cases that require ICU admissions. The project Aimedis would be undertaking would involve tracking the information of patients who receive these antibacterials. Aimedis would gather data about the disease, the state of the patient, treatment given, outcomes, post-discharge care up to a limited time.
Using AI and the power of blockchain, Aimedis would be able to analyse this data that could be used to identify patients that might need similar care, all the while equipping the medical personnel with potential new side-effects, even after discharge. This way, the overall patient experience would be better in the days to come.
Notable partners for this project are SRH group of hospitals, the 7th largest chain of hospitals in Germany. There are talks with other hospitals for potential partnerships as well.
What this news means to an investor
A project by a major pharmaceutical company like Pfizer is a big deal! And, more and more hospitals are getting onboard with us. In addition, other pharmaceutical companies, as well as Insurance players, are interested in this project! This highlights the faith the Healthcare industry has in the future of AI.
So, as in investor in Aimedis, you can rest assured that your investment has a huge potential. We have a sound team and promising offerings that are reasonably priced – a recipe for success. So if you are an investor, you can relax.
And if you are on the fence, are you interested in being part of the trillion dollar industry? You can be a part of it today by participating in the Aimedis pre-sale. Get 25% bonus for your AIM tokens. The pre-sale is happening and you can get your own tokens here.